At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 174 enrolled
Drug / intervention
rasagiline mesylate +1 moredrug
Likely dose
rasagiline mesylate 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Sep 16, 2009·Updated Feb 26, 2015
In Brief
A Phase 2 clinical trial evaluating rasagiline mesylate and placebo for Multiple System Atrophy. Completed, enrolled 174 participants across 47 sites in 12 countries.
Detailed Summary
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple System Atrophy
CountriesAustria, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Spain, United Kingdom, United States
CollaboratorsH. Lundbeck A/S
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartDec 2009
Primary CompletionOct 2011
TodayJul 2026
First PostedSep 16, 2009
Enrollment StartDec 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.8 years ago
Interventions
rasagiline mesylatedrug
rasagiline 1 mg tablet/day for 48 weeks
placebodrug
placebo tablet for 48 weeks